Terns Pharmaceuticals (NASDAQ:TERN) Earns “Equal Weight” Rating from Barclays

Terns Pharmaceuticals (NASDAQ:TERN)‘s stock had its “equal weight” rating reaffirmed by stock analysts at Barclays in a research note issued to investors on Monday,Benzinga reports. They currently have a $53.00 target price on the stock, down from their previous target price of $56.00. Barclays‘s price objective points to a potential upside of 0.53% from the stock’s current price.

Other equities analysts also recently issued reports about the company. HC Wainwright reaffirmed a “neutral” rating and issued a $53.00 price target (down from $60.00) on shares of Terns Pharmaceuticals in a report on Wednesday, March 25th. UBS Group upgraded shares of Terns Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 4th. TD Cowen cut shares of Terns Pharmaceuticals from a “buy” rating to a “hold” rating and set a $53.00 target price for the company. in a report on Thursday, March 26th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $70.00 target price on shares of Terns Pharmaceuticals in a research report on Wednesday, December 10th. Finally, Oppenheimer lifted their price target on shares of Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $56.30.

Terns Pharmaceuticals Price Performance

Shares of NASDAQ TERN opened at $52.72 on Monday. The business has a 50-day moving average of $41.93 and a two-hundred day moving average of $30.00. The company has a market capitalization of $5.47 billion, a price-to-earnings ratio of -51.18 and a beta of -0.31. Terns Pharmaceuticals has a 1 year low of $1.87 and a 1 year high of $53.19.

Terns Pharmaceuticals (NASDAQ:TERN) last released its quarterly earnings data on Thursday, April 2nd. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. As a group, equities research analysts expect that Terns Pharmaceuticals will post -1.19 earnings per share for the current year.

Insider Activity at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 71,339 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $38.10, for a total value of $2,718,015.90. Following the completion of the sale, the chief executive officer owned 138,976 shares in the company, valued at approximately $5,294,985.60. The trade was a 33.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Emil Kuriakose sold 1,155 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the transaction, the insider owned 50,365 shares in the company, valued at approximately $1,942,578.05. This trade represents a 2.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 170,409 shares of company stock worth $6,563,769. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Commodore Capital LP acquired a new stake in shares of Terns Pharmaceuticals during the third quarter worth about $42,807,000. Vestal Point Capital LP acquired a new position in Terns Pharmaceuticals in the 4th quarter valued at about $181,800,000. Avoro Capital Advisors LLC purchased a new stake in Terns Pharmaceuticals during the 4th quarter valued at approximately $175,740,000. Janus Henderson Group PLC purchased a new stake in Terns Pharmaceuticals during the 4th quarter valued at approximately $136,496,000. Finally, Capitolis Liquid Global Markets LLC acquired a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $123,026,000. 98.26% of the stock is currently owned by institutional investors and hedge funds.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.